
Topic
Biosimilars
Follow-on biologics, reference-product erosion, payer switching, launch sequencing, and specialty-channel uptake.

Pricing & Access· May 27, 2026 · 12 min read

Biosimilars· May 27, 2026 · 11 min read
Xolair and Omlyclo omalizumab access guide

Pricing & Access· May 24, 2026 · 12 min read
IL-23 inhibitor access landscape: Skyrizi, Stelara, Tremfya, Omvoh, and Ilumya in 2026
By Ran Chen#Immunology#IL-23 Inhibitor#Coverage Access

Biosimilars· May 23, 2026 · 10 min read
Remicade biosimilars: FDA status, payer coverage, switching, and coding
By Ran Chen#Biosimilars#Coverage Access#Payer Policy

Biosimilars· May 22, 2026 · 9 min read
Avastin biosimilars: FDA status, interchangeability, payer coverage, and switching
By Ran Chen#Biosimilars#Oncology#Coverage Access

Biosimilars· May 22, 2026 · 10 min read
Rituxan biosimilars: FDA status, interchangeability, payer coverage, and switching
By Ran Chen#Biosimilars#Oncology#Coverage Access

Biosimilars· May 21, 2026 · 8 min read
Eylea biosimilars: FDA status, interchangeability, launches, and payer coverage

Biosimilars· May 21, 2026 · 7 min read
Herceptin biosimilars: FDA status, payer coverage, coding, and switching
By Ran Chen#Biosimilars#Oncology#Coverage Access

Biosimilars· May 20, 2026 · 9 min read
Humira biosimilars compared: FDA status, interchangeability, payer coverage, and switching

Biosimilars· May 20, 2026 · 11 min read